https://doi.org/10.55788/2f8ab8ea
Prof. Kausik K. Ray (Imperial College London, United Kingdom) presented the results of the phase 3, international, multicentre, randomised, double-blind, placebo-controlled BETonMACE trial. This study aimed to determine whether modulating epigenetics with the selective bromodomain and extra-terminal (BET) protein inhibitor apabetalone is safe and effective in reducing CV risk [1]. Patients with type 2 diabetes mellitus, ACS within the preceding 7-90 days, and low HDL-C (≤40 mg/dl for men and ≤45 mg/dl for women) were randomised to receive either apabetalone (100 mg orally, twice a day; n=1,212) or matched placebo (n=1,206) in addition to standard-of-care therapy, e.g. intensive or maximum-tolerated treatment with atorvastatin or rosuvastatin. The primary outcome of the study was the time to CV death, non-fatal MI, or non-fatal stroke. A key secondary outcome was time to CV death, non-fatal MI, non-fatal stroke, or hospitalisation for unstable angina or urgent/emergency coronary revascularisation.
Apabetalone changed HDL-C from baseline at 100 weeks by 16.2% versus 10.4% (P=0.001). Over a median follow-up of 26 months, the primary outcome occurred in 10.3% and 12.4% of patients treated with apabetalone versus placebo, respectively (HR 0.82; 95% CI 0.65-1.04; P=0.11). The rate of adverse events was similar across treatment groups, with 830 patients (68.5%) in the apabetalone arm and 820 (67.9%) in the placebo arm reporting at least 1 adverse event. However, discontinuation of treatment due to elevated liver function tests was more frequent in the apabetalone arm. The conclusion presented was that apabetalone has an adequate safety profile, and although HDL-C was significantly reduced from baseline at 100 weeks, no differences could be derived for patients with regard to CV death, non-fatal MI, or non-fatal stroke.
Posted on
Previous Article
« PARAGON-HF: Benefits for women and lower ejection fraction Next Article
Colchicine: no difference in peri-procedural cardiovascular events 30 days post-PCI »
« PARAGON-HF: Benefits for women and lower ejection fraction Next Article
Colchicine: no difference in peri-procedural cardiovascular events 30 days post-PCI »
Table of Contents: AHA 2019
Featured articles
New Approaches to CVD Risk Reduction
Phase 3 BETonMACE trial did not meet its primary endpoint
Inclisiran safely halves LDL-Cholesterol
Colchicine prevents cardiovascular events
Interventional Management for Acute Coronary Syndrome
Drop aspirin after 3 months in non-STEMI ACS patients on dual antiplatelet therapy
Immediate coronary angiography after cardiac arrest does not improve survival
Complete revascularisation for obstructive non-culprit lesions with vulnerable plaque
Colchicine: no difference in peri-procedural cardiovascular events 30 days post-PCI
Intra-aortic balloon pump better than Impella: new observational data
Results for the Ischemia Trials: To Intervene or Not to Intervene
ISCHEMIA trial: Invasive treatment only better for angina burden
Controversies in Contemporary Management of Aortic Stenosis
Full GALILEO results: Why did rivaroxaban fail after TAVR?
Balloon-expandable better than self-expanding transcatheter heart valves
RECOVERY: Benefit of early surgery in asymptomatic severe aortic stenosis
Guidelines: Updates and Controversies
New guidelines on the prevention of cardiovascular conditions
Trials in Electrophysiology and Left Ventricular Function
RENAL-AF trial: Apixaban similar to warfarin
Apple Heart Study: Not just for atrial fibrillation
Early apixaban safe as secondary prevention of stroke from AF
Carvedilol does not improve exercise performance in Fontan patients
New Frontiers in Lipid Therapy
Icosapent ethyl plus statins reduces total plaque volume
ORION-9: Inclisiran RNAi halves LDL in familial hypercholesterolaemia patients
New RNAi therapies to reduce triglycerides: 2 studies show favourable results
Targeting LDL-C <70 mg/dL is better than 100 mg/dL after stroke
Challenges in Heart Failure Management
FUEL trial: Udenafil improves some exercise measurements in Fontan
DAPA-HF: Dapagliflozin also good for heart failure patients without diabetes, of any age, or any health status
PARAGON-HF: Benefits for women and lower ejection fraction
Related Articles
February 26, 2020
Phase 3 BETonMACE trial did not meet its primary endpoint
February 26, 2020
FUEL trial: Udenafil improves some exercise measurements in Fontan
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com